AstraZeneca Delays Final Results of Failed Lung-Cancer Trial
- Mystic trial results to be released in second half, not first
- Astra testing its Imfinzi drug alone and in combination
This article is for subscribers only.
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live with and without the company’s treatment.
The study is continuing “to ensure we have the sufficient number of events to appropriately analyze overall survival,” Karen Birmingham, a company spokeswoman, said in an email. The final analysis, expected in the first half, will be released in the second half instead, the drugmaker said in a statement Monday.